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Introduction
Adherence is defined as “the extent to which the patient’s 
behavior matches agreed recommendations from the pre-
scriber” (Horne et al., 2005, p. 33) and is recognized as a 
complex behavior that varies between individuals 
(Kahwati et al., 2016). Low adherence to treatment is a 
global health problem that has been linked to poorer out-
comes such as increased morbidity, mortality, and other 
costs across a range of clinical conditions (Conn & 
Ruppar, 2017), including chronic health conditions such 
as cystic fibrosis (CF).
Adherence to Nebulizer Treatments in CF
CF is a medical condition affecting around 0.7 people in 
every 10,000 people in the United States and Europe 
(Farrell, 2008), including around 10,400 people in the 
United Kingdom (Cystic Fibrosis Trust, 2012). It is a life-
limiting disease and, although life expectancy rates have 
increased, median survival is projected to be 47 years 
(Cystic Fibrosis Trust, 2018). CF is a genetic condition 
characterized by a buildup of sticky mucus that predomi-
nantly affects not only the lungs, but also the digestive 
system and other organs. It is typified by repeated infec-
tions of the lower respiratory tract that cause difficulty in 
breathing, leading to lung damage and ultimately death 
from respiratory failure.
Medications to improve respiratory function, includ-
ing mucolytics and antibiotics delivered by nebulizers, 
have been shown to be effective in reducing exacerba-
tions and preserving lung function (Briesacher et al., 
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Abstract
Forgetting is often cited as a reason why people struggle to adhere to treatments for chronic conditions. Interventions 
have tried to improve forgetting behavior using reminders. We used a discursive psychological approach to explore 
differences in how high and low adherers constructed forgetting their nebulizer treatments for cystic fibrosis. Interviews 
were conducted with 18 adults from a cystic fibrosis center in the United Kingdom. High adherers constructed 
forgetting treatments as occasional lapses in automaticity and temporary lapses in memory that they found easy to 
repair. Low adherers utilized forgetting to normalize more consistent nonadherence to treatments. However, it 
is important to contextualize forgetting as a discursive resource that helped these participants to negotiate moral 
discourses around adherence to treatment that reminder interventions cannot address; we therefore recommend a 
more behavioral, patient-focused, theory-driven approach to intervention development.
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2011; Eakin, Bilderback, Boyle, Mogayzel, & Riekert, 
2011; Ryan, Singh, & Dwan, 2011; Smith, Rowbotham, 
& Regan, 2018; Yang & Montgomery, 2018). However, 
consistent with other chronic conditions, adherence to 
treatment is low, with the median rate of nebulizer adher-
ence of adults in clinical practice ranging from 31% to 
53% for inhaled antibiotics and from 53% to 79% for 
inhaled mucolytics (Eakin et al., 2011).
Research has identified a number of barriers and facil-
itators to adherence in the adult and pediatric population 
with CF, including to nebulizer treatments. Commonly 
reported barriers to adherence include treatment burden, 
practical issues such as collecting prescriptions, and lack 
of time to do treatments; competing goals including a 
desire to be “normal”; lack of perceived treatment effec-
tiveness and understanding of treatment recommenda-
tions; negative feelings about nebulizers or more general 
anxiety and depression; social and work demands; per-
sonal characteristics; current state of health; and forget-
ting (Abbott, Havermans, & Hart, 2009; Arden, Drabble, 
O’Cathain, Hutchings, & Wildman, 2019; Arias-Llorente, 
García, & Martín, 2011; George et al., 2010; Hogan, 
Bonney, Brien, Karamy, & Aslani, 2015; Horky, Sherman, 
& Polvinen, 2014; Lask, 1994; Macdonald et al., 2016; 
Plummer, Costall, & Torry, 2008; Sawicki, Heller, 
Demars, & Robinson, 2014).
Reported facilitators of adherence include accessibil-
ity and portability of treatment, adherence as part of an 
individual’s identity and maintaining control, awareness 
of the importance of treatment, social support, and hav-
ing a routine (Arden et al., 2019; Arias-Llorente et al., 
2011; Foster et al., 2001; George et al., 2010; Hogan 
et al., 2015; Hoo, Boote, Wildman, Campbell, & Gardner, 
2017; Horky et al., 2014; Plummer et al., 2008; Sawicki 
et al., 2014).
Forgetting to take medication has been identified as a 
major barrier for both the adult and pediatric population 
with CF (Abbott et al., 2009; Bregnballe, Schiøtz, Boisen, 
Pressler, & Thastum, 2011; Dziuban, Saab-Abazeed, 
Chaudhry, Streetman, & Nasr, 2010; George et al., 2010; 
Horky et al., 2014; Modi & Quittner, 2006; Owen & 
John, 2016; Plummer et al., 2008; Sawicki et al., 2014). 
For example, Sawicki and colleagues (2014) reported 
that 29% of adolescent participants cited forgetting as the 
reason for not undertaking their nebulizer treatments. 
However, two smaller studies in adult patients have 
started to question the role of forgetting in adherence 
behavior, suggesting that nebulizer treatments in adults 
may be so routinized that forgetting is not an issue (Hogan 
et al., 2015). In a study of the differences in barriers and 
facilitators to adherence of nebulizer treatments between 
high and low adherers, Arden et al. (2019) found that for-
getting was given as a reason for nonadherence by adults 
regardless of whether they had high or low adherence, 
suggesting that addressing forgetting may not be a useful 
way to improve adherence.
Moral Issues in Nonadherent Behavior
In the adherence literature, nonadherence has been cate-
gorized as intentional or unintentional (Horne et al., 
2005). Intentional nonadherence is when people make a 
conscious, deliberate decision not to adhere to their treat-
ment either some or all of the time and is indicative of 
low motivation to adhere. Unintentional nonadherence is 
where people miss treatments inadvertently for reasons 
out of their control (Gadkari & McHorney, 2012) even 
though they are motivated to adhere.
The term adherence tries to move away from norma-
tive judgments about good (compliant) and bad (noncom-
pliant) behavior, to emphasize the patient’s right to 
choose whether to follow the prescriber’s recommenda-
tions (Horne et al., 2005). However, there is an underly-
ing assumption that the patient should follow adherence 
advice because it is rational to maintain good health, thus 
creating a normative expectation that patients will adhere 
to treatment unless there is a good reason not to. Not fol-
lowing this assumption means the patient’s credibility as 
a good person who is morally adequate (Steele, 1988), 
and their identity as a “good patient,” may be questioned. 
In a study of self-management of long-term conditions 
(stroke, diabetes, and colorectal cancer), Ellis et al. (2017) 
defined the “good self-manager” as someone who takes 
treatments within the medical parameters set by the health 
service. They argued that this definition assumes that the 
patient chooses to adhere to treatment and has the ability 
to control any behavioral change to adhere. However, this 
fails to recognize that taking recommended treatments 
may not be what individuals want because patients can 
make rational decisions to not adhere that make sense to 
them (Donovan & Blake, 1992). Thus, McHorney (2016) 
argued that nonadherence means that “issues important to 
the patient were not addressed” (p. 473). Furthermore, 
behavioral change may be difficult for individuals.
Research suggests that people can be unaware of their 
reasons for nonadherent behavior (e.g., Wegner, 2004). 
Navigating assumptions around expectations that patients 
will do their treatments creates a moral dilemma for the 
patient: How do they maintain their identity as a good 
patient if they do not adhere to treatment, even if it is 
based on what the patient perceives as a perfectly rational 
decision or something outside of their ability to change?
With regard to forgetting as a reason for nonadher-
ence, forgetting is commonly understood as a lapse in 
memory that happens occasionally unless there is dam-
age to the memory through accident or ill health (Spear, 
2014) and is thus unintentional. However, in a survey of 
adherence behavior in 24,017 adults with chronic 
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conditions such as asthma or diabetes, Gadkari and 
McHorney (2012) questioned whether forgetting was 
really unintentional. They found that forgetting, along 
with other unintentional nonadherence behaviors, such 
as carelessness, mediated the relationship between medi-
cation beliefs and intentional nonadherence. They sug-
gested that forgetting might instead predict future 
intentional nonadherence to treatment.
A Discursive Psychological Approach
A discursive psychological approach focuses on language 
as action, considering how people utilize language during 
interactions to construct particular versions or realities, 
and the functions these constructions serve (Potter & 
Wetherell, 1987). Language is thus “a tool to get things 
done” (Potter & Wetherell, 1987, p. 87), for example, to 
justify a particular action (Pomerantz, 1986) such as 
adherent or nonadherent behavior.
Although naturally occurring talk is preferred to inter-
views as the optimal way to consider language in use, 
McAvoy (2016, p. 103) has argued that “interviews 
reproduce culturally available discursive resources for 
making sense of particular meaning-making moments”. 
Interviews provide a way for researchers to enquire pur-
posely about a particular topic, such as adherence to neb-
ulizer treatments, while allowing talk about forgetting to 
emerge more naturally during speech, therefore enabling 
the researcher to examine the function that it serves. 
Discursive psychology is also interested in how credibil-
ity is maintained during talk. In terms of adherence, this 
includes the moral aspects of adherence behavior—that 
there is a common understanding that patients should be 
adhering to treatment—and thus how talking about non-
adherence potentially creates the need to address moral 
judgments and normative expectations about adherent 
and nonadherent behavior (Bergmann, 1998). Attending 
to the discursive strategies that speakers utilize to con-
struct their accounts, and particularly the differences 
between high and low adherers, could enable the func-
tions that forgetting talk served to be made more visible, 
in particular, how speakers use forgetting talk to justify 
nonadherence including avoidance of accepting responsi-
bility for their nonadherence.
Method
We undertook the research reported here as part of a 
larger study—the Adherence to nebulizer treatments in 
adults with Cystic Fibrosis (ACtiF) study. ACtiF is a 
5-year program to develop and evaluate a theory-based 
complex intervention to improve nebulizer adherence in 
adults with CF. The qualitative interview study reported 
in this article was undertaken at the beginning of the 
ACtiF program, as the first step in developing an inter-
vention to improve nebulizer adherence, by understand-
ing the barriers and facilitators to nebulizer adherence in 
adults with CF (Arden et al., 2019). For more information 
about the intervention and pilot feasibility study, also see 
the work by Hind et al. (2019).
Participants
We recruited adults with CF (defined as aged 16 years 
and above) from a hospital-based CF center in the north 
of the United Kingdom. We used purposive sampling to 
approach adults with different objectively measured 
adherence levels. We also maximized diversity within the 
sample by approaching adults of different genders, ages, 
and socioeconomic backgrounds. We approached 21 
adults for interview, from whom 20 consented and 18 
were interviewed. Participants were mostly male, and 
well distributed across age groups, adherence levels, and 
social deprivation quintiles, with the exception of a lack 
of participants from highly affluent areas. Supplemental 
Table describes participant characteristics and levels of 
objective adherence. All participants were White British, 
which is representative of the CF population in the United 
Kingdom. Most participants had been diagnosed with CF 
at birth or shortly after, although two participants had 
been diagnosed during childhood, and two as adults. 
Twelve participants were single and three had children. 
Nine participants worked or studied full-time, two worked 
or studied part-time, four were not working, and three had 
caring responsibilities.
Interviews
We obtained ethical approval from the National Health 
Service (NHS) research ethics committee (REC) South 
Central–Hampshire A (14/SC/1455). I (Sarah) arranged 
and conducted all interviews. I invited participants by let-
ter or email, followed up by a telephone call or emails 
allowing further discussion before deciding whether to 
take part. I obtained written informed consent from all 
participants including that objective adherence data 
would be discussed during the interview. I conducted 
interviews between April and August 2015, which took 
place in participants’ homes or the hospital-based unit 
depending on their preference.
Each interview followed the same format using a topic 
guide to help cover all aspects of nebulizer adherence, but 
leaving the interview open so that the participant could 
describe their own approach to adherence. I started inter-
views by asking participants general questions about liv-
ing with CF and undertaking any treatments before 
focusing on nebulizer usage. I then introduced adherence 
graphs displaying the participant’s personalized nebulizer 
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treatment adherence history for the previous 6 months 
(collected as part of routine treatment in the hospital in 
numerical form and converted to graphical information 
for this study) to prompt discussions about times of high 
and low adherence behavior and what might have caused 
these (see later for details).
I also used prompts related to the theoretical domains 
framework (Cane, O’Connor, & Michie, 2012) to 
explore any other aspects of adherence not already cov-
ered. In this latter part of the interview, there were two 
prompts in the topic guide about forgetting: “How did 
you remember to use your nebulizer?” and “Is using 
your nebulizer something that you always remember to 
do?” However, talk about forgetting occurred naturally 
throughout the interviews as participants described 
times when they had struggled with adherence to their 
nebulizer treatments. Interviews lasted on average 99 
min, ranging from 65 to 147 min.
Objectively measured adherence. One aspect of the inter-
view was the introduction of objective adherence data 
regarding nebulizer treatments into the interview. Adher-
ence to nebulizers, like many other treatments, is usually 
measured via self-report—which has been shown to be 
inaccurate (Daniels et al., 2011). To measure adherence 
objectively, we utilized a chipped nebulizer (I-Neb®; 
Philips Respironics) that recorded how much treatment 
patients had taken compared with the amount of medica-
tion prescribed.
In our sample, participants were on a range of nebu-
lized treatments. All were on at least one mucolytic treat-
ment to clear mucous, with most having at least a further 
two or three preventive antibiotics. A minority of partici-
pants were on a separate bronchodilator because most 
patients mixed this with their antibiotic treatment. The 
number of daily treatments did not relate to the objective 
adherence level of our participants as the two lowest 
adherers had only one daily treatment, and the two high-
est adherers were taking between two and four daily 
treatments.
Objective adherence was categorized into high 
(≥80%), moderate (50.1%-79%), low (25.1%-50%), or 
very low (≤25%) adherence in the previous 6 months. 
This was based on prior research that has linked high 
adherence (≥80%) to better health outcomes, when com-
pared with low adherence (<50%) (Eakin et al., 2011). In 
addition, we distinguished between very low and low 
adherence (Hoo, Campbell, et al., 2017). Adherence data 
were transformed into graphs of adherence in three for-
mats: overall adherence over the past 6 months, days of 
the week (whereby adherence for each day for the past 6 
months was shown), and time of day (where adherence 
data were shown in 2-hr slots); this was done to help par-
ticipants identify patterns in their adherence.
Transcription and Analysis
Interviews were digitally audio-recorded and tran-
scribed verbatim. Maddy and I analyzed the data using 
framework analysis (Ritchie & Spencer, 1994) to 
describe facilitators and barriers to adherence; this is 
reported in a separate article (Arden et al., 2019). 
During this analysis, I (Sarah) was struck by how both 
high and low adherers talked about forgetting, and that 
it seemed to be fulfilling a function within the discus-
sion of adherence. Therefore, I carried out a further dis-
cursive analysis on transcript extracts where participants 
spoke about forgetting as a reason for not doing treat-
ments or having problems remembering their nebulizer 
treatments, including talk about use of reminders and 
other cues and prompts.
I retranscribed these extracts using a modified 
Jeffersonian transcription system (see the appendix). 
These new transcripts were read and reread and I applied 
the following questions: (a) How did participants 
describe and explain forgetting behavior? (b) What func-
tions did these descriptions of forgetting behavior fulfill 
within this interaction? (c) Did individuals in different 
adherence categories use forgetting in different ways to 
explain nonadherence?
I paid attention to patterns of language and aspects of 
speech such as grammar and word choice, including 
interactional difficulties signaled by hedging with pauses 
(Jefferson, 1989), hesitations and repetitions (Buttny, 
1993), extreme case formulation (Pomerantz, 1986), and 
lists of three parts (Jefferson, 1990), which are used to 
legitimize claims. I also considered modality, which is 
achieved by using tenses of verbs or adverb; for example, 
may/might, could, and sometimes offer less commitment 
to the truth than is, has, or always (Fairclough, 2003).
In discussion with Alicia, we noticed patterns in how 
forgetting was presented by participants with different 
adherence levels and how this enabled them to avoid talk-
ing about other reasons for nonadherence. I used adher-
ence levels to organize the discursive analysis. I then 
presented analysis of extracts to Alicia; these were dis-
cussed in depth, and she challenged my interpretation and 
analysis in terms of clarity and patterns of speech. A draft 
of the findings was circulated to the other authors, includ-
ing a patient representative (Dan), for further challenge 
and refinement.
Results
In the results, participants are given a number depending 
on their adherence level, from the lowest (1) to the high-
est (18) adherence. Conventionally, discursive analysis 
would present line-by-line analysis. However, due to the 
limitations of space, and the range of different ways in 
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which participants used forgetting during adherence talk, 
we present less detail to show examples of each theme.
In the extracts, “I” refers to me (Sarah) as the inter-
viewer and “P” to the participant. The sample of extracts 
presented represents the range of functions forgetting 
served within the interactions in the 18 interviews. In this 
analysis, we do not in any way want to suggest that 
patients were deliberately trying to deceive about their 
adherence. Adherence is behaviorally complex, and there 
are many reasons why individuals do not adhere, some of 
which remain unknown to them. However, in talking 
about adherence and nonadherence, patients are required 
to negotiate these underlying moral issues and we believe 
it is important to explore how this happens in conversa-
tions about adherence.
Overview of Forgetting Themes to Justify 
Nonadherence
Fourteen of our 18 participants cited forgetting as a reason 
for nonadherence to nebulizer treatments. Of the 18 par-
ticipants, all but the lowest adherer talked about using dif-
ferent types of reminders to do treatment. We found some 
interesting ways in which forgetting was utilized by par-
ticipants. In light of the moral issues identified in the intro-
duction, we recognize that nonadherence was at times 
difficult for participants to acknowledge. Therefore, we 
have used the term “admit” to show how participants had 
to overcome moral issues during the interviews. We pres-
ent instances where participants admitted nonadherence, 
times when they occasionally forgot their treatment, strate-
gies to normalize nonadherence, and how well reminders 
worked to help them remember to do their treatment.
A summary of themes regarding how participants con-
structed forgetting by adherence level is presented in 
Table 1. A discussion of each theme with example quotes 
is presented below.
Admitting Nonadherence
Admitting nonadherence appeared easier for those with 
higher adherence, with the exception of one participant who 
had zero adherence and was open about nonadherence. For 
example, a very low adherer contested the definition of 
intentional nonadherence I used as “a conscious decision 
not to use your nebulizer,” which caused interactional dif-
ficulty indicated by the long pauses (Jefferson, 1989). My 
use of “conscious decision” was an attempt to ask about 
intentional nonadherence in a different way. The participant 
questioned the meaning as “plan not to take it anywhere” 
and I clarified this as “plans not to use it at a particular time 
because of something” still suggesting intentional nonad-
herence but softening the statement slightly. However, the 
participant was still unable or unwilling to admit planning 
not to do their treatment, using “probably forgetting” to 
explain times of nonadherence as preferable to admitting 
(at least consciously) not to adhere to treatment:
I: are there times when you’ve made like a conscious 
decision not to use your nebulizer?
P: (2 secs) erm (4 secs) what like sort of plan not to take it 
anywhere with me?
I: Yeah or plans not to use it at particular time because of 
something?
P: Not that I’ve planned. I’ve probably forgot (3 secs) to take 
it. But I’ve not planned not to take it with me. (Very low 
adherer)
A high adherer distinguished between forgetting (not a 
choice) and intentional nonadherence (choosing to not 
adhere), but this required them to own up to this behavior 
by saying, “I will be honest,” suggesting awareness that 
nonadherence is not good behavior:
I will be honest, it’s weren’t that I forgot. I just chose not to. 
(High adherer)
Forgetting as an Occasional Lapse in 
Automaticity
Some participants with high adherence described adher-
ence behavior as a habit that was automatic or “hard-
wired,” therefore making forgetting less likely. For one 
high adherer, a reduction in prescribed treatment could 
feel like forgetting because their routine was so automatic 
that they felt its absence:
P: Just because it’s hardwired isn’t it?
I: (laughs) Whatever it is, is just like-
P: If I come off these many antibiotics, from twice a day, I 
feel like I’m forgetting something. You know as soon as I 
finish them if I’m not taking them I start and-
I: What should I be doing?
P: Yeah. (High adherer)
Forgetting as a Temporary Lapse in Memory
Participants with high adherence also constructed forget-
ting as a temporary lapse in memory corrected by taking 
treatment as soon as they remembered, rather than not 
adhering:
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And if I was coming back and then going straight back out 
and I knew that I needed to take it. Then I just totally forgot. 
I was out and remembered. (High adherer)
One participant with moderate adherence also constructed 
forgetting as a temporary lapse that they needed to fix 
later on. However, remembering the later treatment 
appeared more effortful than for those with higher adher-
ence, indicated by the use of “it forces you to think” and 
“you’ve gotta remember”:
It forces you to think, right, now you’ve gotta remember to 
take it this afternoon because you forgot the morning’s one. 
(Moderate adherer)
Strategies to Normalize Nonadherence
Participants showed awareness of normative expectations 
to do treatments. This created difficulties in admitting to 
nonadherence, which then needed to be justified in a 
socially acceptable way. Forgetting was one way partici-
pants explained nonadherence and was utilized in a num-
ber of different ways: as humorous behavior, as a socially 
acceptable justification, as avoidance of CF, as the binary 
opposite of adherence, and as routinizing nonadherence.
Forgetting as humorous behavior. In the following exam-
ple, we all (the interviewer, interviewee, and their wife) 
laughed about this moderate adherer only taking half 
their treatment despite the potentially life-limiting conse-
quences of this action. The participant revealed a norma-
tive understanding that they should adhere to treatment “I 
should take it” and that adherence is good behavior “that’s 
not good.” When the participant used forgetting that 
morning to explain nonadherence, they laughed and the 
others in the room joined in. It is funny because after 
acknowledging that treatment is important, they have 
been found out and feel the need to explain what has gone 
wrong. Forgetting as humorous behavior helped to close 
down the conversation:
That’s not good, I’m only taking it 50 percent of the time, 
well 55 percent of the time I should take it [wife in 
background: you haven’t had it yet this morning, you’ve 
missed this morning ((laughs))], I forgot, yeah ((laughs)). 
((All laugh)). (Moderate adherer)
Using socially acceptable justifications for forgetting. Both 
high and low adherers normalized nonadherence by sug-
gesting that simply forgetting was due to a lack of routine, 
socializing, being too busy, being tired or apathetic, or due 
to knowledge that treatments should be taken at a number 
of hours after a previous treatment. At times, forgetting 
appeared to work as both a synonym for nonadherence 
and as an explanation for nonadherent behavior that par-
ticipants did not understand. A very low adherer claimed 
that socializing led to forgetting, which allowed them to 
talk about intentional nonadherence in a more socially 
acceptable way, rather than talking about choosing to go 
out instead of prioritizing their treatment. The use of 
“might” suggests this is not a definite course of action 
(Fairclough, 2003); this was followed by talking about 
repairing this behavior by playing “catch up” the follow-
ing day to persuade me that this is not common behavior:
Sometimes, if then someone says “oh let’s go out” you know 
I might then, that might be the time I might forget my 
Table 1. A Summary of Themes by Adherence Level.
Constructions of Forgetting
Number of Participants by Adherence Level
Very Low
N = 5
Low
N = 5
Moderate
N = 4
High
N = 4
Admitting nonadherence 1 0 1 1
Occasional lapse in automaticity 0 0 0 3
Temporary lapse in memory 0 0 2 4
Struggling to admit nonadherence 1 1 0 0
Strategies to normalize nonadherence:
 Forgetting as humorous behavior 0 0 1 0
 Using socially acceptable justifications for 
forgetting treatment (e.g., busyness, 
socializing, tiredness or apathy, and 
treatment-taking knowledge)
2 3 2 4
 Forgetting as avoidance of cystic fibrosis 3 0 0 0
 Forgetting as the binary opposite of adherence 0 2 0 0
 Forgetting as routinizing nonadherence 3 0 0 0
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evening one. And it just never comes back to mind until sort 
of the next day and I think “oh I’ve actually missed my 
evening dose the night before” but then you know I’m sort of 
trying to play catch up the next day. (Very low adherer)
Some participants constructed forgetting as being too 
busy to adhere. In the following extract, talk of forgetting 
and a “busy life” helped the participant to normalize their 
lack of treatment-taking routine. This moderate adherer 
started this extract talking about watching a popular tele-
vision program, Britain’s Got Talent, as “just busy life.” 
However, perhaps realizing that this excuse needed justi-
fying further, they added having “other things on” or 
going out, which created a three-part list that gave more 
plausibility to the justification (Jefferson, 1990). In a later 
part of the extract, the participant mentions forgetting, in 
addition to a busy life or getting into a “regime,” so the 
listener is unclear about whether forgetting is due to a 
busy life or in addition to a busy life. The description 
“regimented regime” implies that routines offer a strictly 
controlled, unappealing alternative to nonadherence, and 
the listener is left unclear as to whether the participant is 
unable to establish a routine in the context of a busy life, 
finds routines unappealing, or does not fully understand 
their nonadherence behavior:
Oh it’s just, I don’t know, it’s just busy life, you just, we’d be 
sat watching, I don’t know, Britain’s Got Talent (.) “ah I 
didn’t take me! Ah!” and that’s how it goes, you just forget 
or you’ve, you’ve got other things on, or you’ve gone out 
and, so in terms of not doing your treatment or missing stuff 
it’s purely on a basis where you’ve, you’ve got a busy life or 
you’ve forgot or you can’t get into a regimented (.) regime of 
taking stuff. (Moderate adherer)
A high adherer also admitted nonadherence by present-
ing a moral dilemma between two socially unacceptable 
courses of action; nonadherence (forgetting) in some 
situations is reasonable “you just can’t” if it represents a 
temporary lapse that cannot be repaired without commit-
ting a more socially unacceptable action “you are not just 
going to come home from someone’s birthday to do your 
medication”:
There is just going to be times when you just can’t, like it 
might be someone’s birthday, and you might have forgot to 
do it. And you are not just going to come home from 
someone’s birthday to do your medication. (High adherer)
Forgetting as avoidance of CF. Some participants constructed 
nebulizer treatments and prompts to do treatments as 
unwanted reminders of CF. Forgetting worked to persuade 
the listener that it is unacceptable to expect someone to 
think about CF all of the time; therefore, it is acceptable to 
forget your treatment. This very low adherer described a 
period of not adhering to treatment by putting off treatment 
at different time points until they forgot to do it, indicated 
by “it will completely slip my mind and I just forget to do 
it altogether.” The use of forgetting persuades the listener 
that the nonadherent behavior is not a choice but a series of 
smaller decisions that add up to forgetting, rather than 
intentional nonadherence. However, I called into question 
the plausibility of this statement and the participant gives 
another reason for nonadherence; that they want to be 
“normal,” more like “someone my age.” Adherence is thus 
presented as a barrier to normality that justifies the inten-
tional nonadherence in a plausible way:
At the minute it’s just like out the window. Like I’ll say “ah 
I’ll do that in the morning.” Get up in the morning, and I’ll 
find something else to do, and it won’t be till later on in the 
day and I’m like “oh I should have done that, oh I’ll do it 
later when I get in then.” Get home later and it will 
completely slip my mind and I just forget to do it altogether.
I-Ok, do you think that’s erm, an intentional thing or?
P-I think it’s more like a blocking and like I put out my 
mind. Like I say if I block it, it isn’t there sort of thing [yeah] 
it’s the way it is
I-How does it help you if you block it?
P-Because like, if I don’t, if I block it, I don’t think about it 
so it’s not there sort of thing I feel. So I can, I don’t know 
how to say, not be normal, but more of someone my age sort 
of thing. (Very low adherer)
Forgetting as the binary opposite of adherence. A low 
adherer constructed adherence behavior as “easy” and 
“simple”; you either remember to do your treatment or 
you forget to do it. This construction normalized nonad-
herence, making it harder to open up the conversation 
about reasons for nonadherence:
I just I either remember or I don’t, it’s as easy, it’s as simple 
as that. (Low adherer)
Another low adherer constructed forgetting as the binary 
opposite of perfect adherence, which allowed the partici-
pant to normalize nonadherence because no one can be 
perfect all the time. After openly admitting to “times 
when you don’t do” treatment, the explanation for this 
nonadherence was contrasted with doing treatment 100% 
of the time, which was described as “idealistic,” “perfect” 
behavior that is essentially unachievable. The addition of 
“never,” an extreme case formulation, legitimizes never 
forgetting as unrealistic (Pomerantz, 1986):
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I think there are times when you don’t do them. I think you 
would be very err idealistic to just say “oh yes I’m perfect and I 
do them all the time and I never forget.” (Low adherer)
Forgetting as routinizing nonadherence. Other participants 
with low adherence constructed many smaller instances of 
forgetting that added up to a period of low adherence to 
normalize nonadherence. In the following extract, the par-
ticipant justified why they had not adhered while maintain-
ing their identity as a good patient who is improving their 
adherence. Participants initially constructed forgetting as 
routinized examples of occasional nonadherence “some-
times it can lead to sort of forgetting a bit more often.” 
However, to maintain their identity as a good patient, the 
participant suggested that recently forgetting had become 
“known,” “more conscious,” and had improved “trying to 
find more ideas of how to prevent the forgetfulness.” Thus, 
they are able to maintain their identity as a good patient 
who is trying to improve their adherence in the context of 
someone who is not currently adhering:
I think the consequences of that [missing your nebulizer] is 
you know sometimes it can lead to sort of forgetting a bit more 
often but I think you know the times that I forgot recently, I’ve 
sort of known about it and I’ve been more conscious about it 
and I think finding more ideas trying to find more ideas of how 
to prevent the forgetfulness. (Very low adherer)
In the following extract, the participant suggested that 
making smaller conscious decisions to put off treatment 
leads to forgetting, “and then I forget,” rather than making 
an intentional decision not to do treatment. This sugges-
tion is made more plausible by suggesting that it is an 
occasional disruption that only occurs at weekends to their 
usual “regimented routine” that the listener assumes hap-
pens during the week. It is only my knowledge of the 
objectively measured very low adherence of this partici-
pant that calls this into question:
But also on a weekend if I don’t get up and we’re not going out 
there’s not that regimented routine so I just think “oh I’ll do it 
in a bit” and then a bit comes and I think I’ll do it in a bit and it 
just doesn’t get done and then I forget. (Very low adherer)
Using Reminders to Address Forgetting
Thirteen of the 18 participants talked about currently or 
having in the past used some form of reminder to do their 
treatment, for example, an alarm, chart, or visual prompt 
such as leaving their nebulizer where they could see it. Of 
those who talked about reminders, five participants, four of 
whom had the highest adherence, described having a 
strong routine, which rendered reminders redundant. 
However, they did think that reminders could be useful at 
times when treatments changed, and two of them had 
previously used visual prompts. In contrast, participants 
with very low to moderate adherence found reminders had 
limited usefulness, actively ignored alarms on phones, and 
described them as “nagging” (low adherer) or annoying:
My psychiatrist once mentioned [reminders], tried that and 
set alarms on my phone. And my phone just nearly, on a bad 
day, ended up through the window. Shut up. (Very low adherer)
Alternatively, reminders were just another thing to be 
forgotten:
But that’s just something else to remember to tick [] and I 
always forgot to do it so it’s like “oh.” (Low adherer)
Some participants used other people, such as parents, to 
remind them to do their treatment, suggesting a lack of 
self-efficacy. For example, a very low adherer appeared 
to shift responsibility to their parent, signaled in the quote 
below by “you’re going to have to” and “tell me then it 
will remind me”:
And I said to my mum [] you’re going to have to tell me 
“don’t forget your nebulizer” you know “just remind me, tell 
me” then it will remind me to sort of keep going with it. 
(Very low adherer)
Discussion
Using a discursive psychological approach, we found that 
forgetting talk fulfilled discursive functions related to 
both intentional and unintentional nonadherence, rather 
than only the expected unintentional nonadherence 
(Gadkari & McHorney, 2012).
Low Versus High Adherence
In this study, we adopted a novel approach, using chipped 
nebulizer data to compare how talk about forgetting to do 
your treatment differed between high and low adherers. 
Higher adherers appeared to have a clearer understanding 
of their own behavior, creating a conceptual framework 
to explain occasional and temporary lapses of memory 
and routines that could be repaired, drawing on the com-
mon understanding that memory only fails occasionally 
and will be rectified later (Spear, 2014).
Recent research has suggested that reminder interven-
tions may not always be an effective strategy to improve 
adherence (e.g., Choudhry et al., 2017; Kahwati et al., 
2016). We found that reminders were perceived as unnec-
essary by high adherers, perhaps due to their well-estab-
lished routines, and unhelpful and easy to ignore by lower 
adherers, although (visual) cues such as leaving equip-
ment where it is visible seemed to be useful at least when 
establishing adherence habits.
Drabble et al. 9
Our study also adds to understanding of forgetting as 
a reason for nonadherence (e.g., Gadkari & McHorney, 
2012; McHorney, 2016) by identifying how partici-
pants with very low adherence normalized nonadher-
ence by routinizing smaller, occasional lapses into a 
longer period described as forgetting, rather than non-
adherence. Low adherers also contrasted forgetting 
with perfect adherence to persuade the listener that 
some adherence behavior was essentially unachievable, 
shutting down other explanations for nonadherence 
behavior that they found difficult to explain or did not 
understand.
Forgetting as a Way to Address Moral 
Dilemmas in Admitting Nonadherence
The adherence literature has moved from talking about 
compliance, incorporating normative expectations 
about bad and good behavior, to adherence, in which 
the patient decides whether to follow adherence advice 
(Donovan & Blake, 1992; for example, Horne et al., 
2005). However, in this study, both the interviewer and 
participants appeared to share the expectation that par-
ticipants should adhere to treatment, that this repre-
sented good behavior, and that any nonadherence 
needed to be justified.
Admitting nonadherence potentially threatened par-
ticipants’ identities as a “good person” (Steele, 1988) 
and a “good patient or self-manager” who “takes treat-
ments within medical parameters” (Ellis et al., 2017). 
The concept of the good patient draws on Parsons’s 
(1975) sociological concept of the sick role in which a 
patient has an obligation to get better or become health-
ier (Burnham, 2014). Forgetting was one way in which 
participants could explain nonadherent behavior, while 
maintaining the identity of the patient who is doing 
what they can to get better except in situations in which 
it is not possible. Although, more recently, sociologists 
have moved away from the concept of the sick role to 
the patient having control of their treatment (Burnham, 
2014; Donovan & Blake, 1992), in our study, nonadher-
ence still needed to be addressed within verbal interac-
tions. Thus, forgetting became a discursive resource to 
help participants negotiate some of the moral discourses 
around adhering to treatment (Murdoch, Salter, Poland, 
& Cross, 2015).
Participants with very low adherence used avoid-
ance of thinking about having CF as a reason for for-
getting. Avoidance has been identified by others as a 
way of coping with CF (Abbott, Dodd, Gee, & Webb, 
2001) and has been associated with higher self-esteem, 
lower alienation, and discomfort in young adults with 
CF and rated by physicians as an effective coping strat-
egy (Moise, Drotar, Doershuk, & Stern, 1987). In 
health care consultations, there is a recognized power 
imbalance (Joseph-Williams, Elwyn, & Edwards, 
2014). Strategies that normalize nonadherence, similar 
to those found in our study, could deflect attention 
away from a more challenging conversation about non-
adherence, allowing the patient to regain some control 
of the interaction (Conrad, 1985; Herrera, Moncada, & 
Defey, 2017). Forgetting talk may offer patients a way 
to avoid addressing reasons for nonadherence that 
could bring them into conflict with health profession-
als who advocate treatment adherence, while helping 
them to maintain psychological well-being (Arias-
Llorente et al., 2011).
Limitations
There are some limitations to this study. First, the sam-
ple was from a single center that may be different from 
other centers. This center had started to use measure-
ment of objective adherence to medication within clini-
cal consultations, and motivational interviewing to 
address nonadherence, at the time this study was under-
taken. Motivational interviewing is an approach to 
interactions in which ambivalence to behavior change 
is explored and resolved in a nonconfrontational man-
ner (Rollnick & Miller, 1995). The approach of the cen-
ter may have affected patient views of adherence by 
making them more positive or negative toward adher-
ence, or more aware of adherence, but the interviewer 
had no sense in the interviews that this had occurred. In 
addition, motivational interviewing training is not 
unique to this center and may occur in many CF centers 
to some extent.
Second, participants were made aware that they would 
be seeing and discussing graphs of their adherence data as 
part of this interview when agreeing to participate. 
Knowing this may have encouraged participation by 
those more open to talking about nonadherence but also 
created a situation in which (non)adherence was the topic 
of conversation and needed to be justified (Murdoch 
et al., 2015).
Third, the sample had more male participants than the 
CF population. We aimed to get a balance of males and 
females and do not know why this gender imbalance 
occurred. It is possible that our findings relate more to 
men than to women; however, all of the issues identified 
appeared in the small number of females in the study, as 
well as the males.
Implications
Forgetting is often cited as a barrier to adherence in both 
CF (e.g., Abbott et al., 2009; Bregnballe et al., 2011; 
Dziuban et al., 2010; George et al., 2010; Horky et al., 
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2014; Kahwati et al., 2016; Modi & Quittner, 2006; 
O’Toole et al., 2019; Owen & John, 2016; Plummer 
et al., 2008; Sawicki et al., 2014) and other chronic con-
ditions (Gadkari & McHorney, 2012; Horne et al., 2005; 
Ingersoll & Cohen, 2008; Mills et al., 2006; Rathbone 
et al., 2017). We do not claim to have uncovered all the 
different ways in which forgetting is utilized to account 
for nonadherence of nebulizer treatments in CF (Morse, 
2015). However, we found instances where low adherers 
used forgetting to describe intentional nonadherence, 
which has implications for research and practice.
Several measures of subjective adherence make the 
assumption that forgetting is unintentional, for exam-
ple, the five-item Medication Adherence Report Scale 
(MARS-5; Horne & Hankins, 2004) and Morisky 
Medication Adherence Scale (MMAS; Morisky, Green, 
& Levine, 1986). In addition, interventions to improve 
adherence to medication in people with chronic condi-
tions, that only classify forgetting as unintentional non-
adherence, will tend to focus on simple solutions that 
bring adherence back to the forefront of patients’ minds, 
such as email or text reminders to take medication. This 
focus may lead to interventions being developed to help 
participants avoid forgetting that may not be effective 
(e.g., Choudhry et al., 2017).
We suggest that for some types of treatment for some 
conditions, forgetting can mean intentional nonadherence 
(Gadkari & McHorney, 2012); therefore, more complex, 
behaviorally orientated, psychosocial approaches to 
increasing adherence may be needed (Conn & Ruppar, 
2017; Kronish & Moise, 2017; Molloy & O’Carroll, 2017).
Our findings also have implications for health care 
practitioners discussing adherence to treatment with 
patients. Even when patients talk about forgetting treat-
ment, we suggest that health care practitioners should be 
open to other possible explanations for nonadherence that 
patients may feel unable to express openly, or have diffi-
culty identifying, and that there may be aspects other than 
forgetting that patients use to avoid talking about, or to 
justify, nonadherence.
Rather than relying on self-reported adherence that 
may be inaccurate (Daniels et al., 2011), the use of objec-
tive adherence data from chipped nebulizers can help to 
open up patient-led discussions about adherence behav-
ior. This approach recognizes that both patients and staff 
may not know how much someone adheres, or under-
stand why they do or do not adhere (Wegner, 2004), and 
that the best intentions to adhere can be unstable and eas-
ily derailed by contextual factors (Arden et al., 2019). It 
is important that conversations about adherence are 
approached in a nonthreatening way, for example, using a 
motivational interviewing approach (Rollnick & Miller, 
1995). Aspects of motivational interviewing can be used 
as an accompaniment to other behavior change strategies 
(Kahwati et al., 2016) that take a more complex, theory-
driven approach to help patients address difficult behav-
ioral change by addressing aspects such as habit formation 
(Conn & Ruppar, 2017), emotions, and relationships 
(O’Toole et al., 2019).
Conclusion
A discursive psychological approach found that differ-
ences between how high and low adherers of CF nebu-
lizer treatments used forgetting to justify nonadherence 
to nebulizer treatments. Forgetting is usually under-
stood as unintentional nonadherence; however, 
forgetting became a discursive resource to help partici-
pants negotiate some of the moral discourses around 
adhering to treatment.
Appendix
Transcription notation.
Notation Description
Word. A completing intonation (not necessarily a grammatical full stop)
Word, A continuing intonation
Word Emphasis by the speaker on a word or part of a word
Wo- Abrupt termination or word or sound
Wo’d Letters omitted from words or phrases
“Word” Reported speech
(.) Brief pause in the flow of speech
(2 secs) Longer pause, showing the time in seconds of the pause
Don’t you [mm] I mean Bold text in square brackets show interviewer speech which did not break the flow of the interview
((interviewee laughs)) Text in double parentheses and italicized refers to notes about how something was said or to 
something that happened during the interview
[] Omitted speech
[text] Clarificatory information from transcription
(. . .) Inaudible speech
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